Literature DB >> 15817396

Signalling by PI3K isoforms: insights from gene-targeted mice.

Bart Vanhaesebroeck1, Khaled Ali, Antonio Bilancio, Barbara Geering, Lazaros C Foukas.   

Abstract

Phosphoinositide 3-kinases (PI3Ks) generate lipids that control a wide variety of intracellular signalling pathways. Part of this diversity in PI3K actions stems from the broad range of protein effectors of the PI3K lipids. A further layer of complexity is added by the existence of multiple isoforms of PI3K. Gene-targeting studies in the mouse have recently uncovered key roles for specific PI3K isoforms in immunity, metabolism and cardiac function. Remarkably, some of these actions do not require PI3K catalytic activity. In addition, loss-of-expression of certain PI3K genes leads to increased PI3K signalling following insulin stimulation. PI3K gene targeting has, in many cases, led to altered expression of the non-targeted PI3K subunits, making it difficult to exclude that some of the reported phenotypes result from 'knock-on' effects of PI3K gene deletion. Targeting strategies that take into account the complex interplay between members of the PI3K family will be crucial to gain a full understanding of the physiological roles of the isoforms of PI3K.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15817396     DOI: 10.1016/j.tibs.2005.02.008

Source DB:  PubMed          Journal:  Trends Biochem Sci        ISSN: 0968-0004            Impact factor:   13.807


  173 in total

Review 1.  Specific PI3K isoform modulation in heart failure: lessons from transgenic mice.

Authors:  Alessandra Ghigo; Fulvio Morello; Alessia Perino; Federico Damilano; Emilio Hirsch
Journal:  Curr Heart Fail Rep       Date:  2011-09

Review 2.  ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system.

Authors:  De-xin Kong; Takao Yamori
Journal:  Acta Pharmacol Sin       Date:  2010-08-23       Impact factor: 6.150

Review 3.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

4.  Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair.

Authors:  Amit Kumar; Oscar Fernandez-Capetillo; Oscar Fernadez-Capetillo; Ana C Carrera
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

5.  Activity of any class IA PI3K isoform can sustain cell proliferation and survival.

Authors:  Lazaros C Foukas; Inma M Berenjeno; Alexander Gray; Asim Khwaja; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

Review 6.  Molecules in medicine mini-review: isoforms of PI3K in biology and disease.

Authors:  Bart Vanhaesebroeck; Maria A Whitehead; Roberto Piñeiro
Journal:  J Mol Med (Berl)       Date:  2015-12-10       Impact factor: 4.599

7.  PI3Kα inactivation in leptin receptor cells increases leptin sensitivity but disrupts growth and reproduction.

Authors:  David Garcia-Galiano; Beatriz C Borges; Jose Donato; Susan J Allen; Nicole Bellefontaine; Mengjie Wang; Jean J Zhao; Kenneth M Kozloff; Jennifer W Hill; Carol F Elias
Journal:  JCI Insight       Date:  2017-12-07

Review 8.  PI3K signaling in glioma--animal models and therapeutic challenges.

Authors:  Christine K Cheng; Qi-Wen Fan; William A Weiss
Journal:  Brain Pathol       Date:  2009-01       Impact factor: 6.508

9.  Sjögren's syndrome-like disease in mice with T cells lacking class 1A phosphoinositide-3-kinase.

Authors:  Jean S Oak; Jonathan A Deane; Michael G Kharas; Ji Luo; Thomas E Lane; Lewis C Cantley; David A Fruman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-27       Impact factor: 11.205

10.  Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.

Authors:  Barbara Geering; Pedro R Cutillas; Gemma Nock; Severine I Gharbi; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.